International Symposium of Hemotherapy & Cell Therapy

March 21-23, 2024

Sao Paulo, Brazil

Featured Event

Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing

PM Date: Friday, March 22
Time: 3:45 - 4:15PM BRT
Presenter: Vimal Keerthi, Process Development Scientist



Vimal Keerthi

Vimal is a Process Development Scientist in Dr. Steven Feldman’s group at the Stanford Center for Cancer Cell Therapy focusing on developing CRISPR knock-in platforms for non-viral CAR-T manufacturing. Prior to working on non-viral platforms, Vimal worked on the process development of Allogeneic Hematopoietic Stem Cell Transplants and donor derived T-allo10 Tr1 cell therapies at Stanford’s cGMP Laboratory of Cell & Gene Medicine.